Major causes of morbidity and mortality in myeloproliferative neoplasms are represented by
arterial and venous complications, progression to myelofibrosis, and transformation to acute …

Introduction: Sickle cell anemia (SCA) is a severe, inherited hemoglobin disorder affecting
100,000 persons in the US and millions worldwide. Hydroxyurea, a once daily oral …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Background Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical
benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open …

Background: Patients with myeloproliferative neoplasms (MPNs) are reported to be at
increased risk for thrombotic events. However, no population-based study has estimated this …

Background Belantamab mafodotin had single-agent activity in patients with relapsed or
refractory multiple myeloma, a finding that supports further evaluation of the agent in …

Title A guideline for the diagnosis and management of polycythaemia vera A British Society for
Haematology Guideline Authors Mc Page 1 1 Title 1 A guideline for the diagnosis and …

Abstract Objective To document the Mayo Clinic decades-long experience with
myeloproliferative neoplasms (MPNs) and provide mature risk-stratified survival data and …

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including
polycythemia vera (PV), essential thrombocythemia (ET), and primary (idiopathic) …

Polycythemia vera (PV) and essential thrombocythemia (ET) constitute two of the three BCR-
ABL1-negative myeloproliferative neoplasms and are characterized by relatively long …